HomeCompareSNBIF vs NNN

SNBIF vs NNN: Dividend Comparison 2026

SNBIF yields 12.16% · NNN yields 5.68%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SNBIF wins by $19.0K in total portfolio value
10 years
SNBIF
SNBIF
● Live price
12.16%
Share price
$16.45
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.6K
Annual income
$2,595.30
Full SNBIF calculator →
NNN
NNN REIT Inc.
● Live price
5.68%
Share price
$41.89
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.6K
Annual income
$2,637.42
Full NNN calculator →

Portfolio growth — SNBIF vs NNN

📍 SNBIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSNBIFNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SNBIF + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SNBIF pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNBIF
Annual income on $10K today (after 15% tax)
$1,033.43/yr
After 10yr DRIP, annual income (after tax)
$2,206.01/yr
NNN
Annual income on $10K today (after 15% tax)
$482.93/yr
After 10yr DRIP, annual income (after tax)
$2,241.81/yr
At 15% tax rate, NNN beats the other by $35.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNBIF + NNN for your $10,000?

SNBIF: 50%NNN: 50%
100% NNN50/50100% SNBIF
Portfolio after 10yr
$35.1K
Annual income
$2,616.36/yr
Blended yield
7.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

SNBIF
Analyst Ratings
1
Sell
Consensus: Sell
Altman Z
60.9
Piotroski
2/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+7.3% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNBIF buys
0
NNN buys
0
No recent congressional trades found for SNBIF or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSNBIFNNN
Forward yield12.16%5.68%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$44.6K$25.6K
Annual income after 10y$2,595.30$2,637.42
Total dividends collected$18.9K$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusSellHold

Year-by-year: SNBIF vs NNN ($10,000, DRIP)

YearSNBIF PortfolioSNBIF Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$11,916$1,215.81$10,737$617.02+$1.2KSNBIF
2$14,104$1,353.95$11,577$710.93+$2.5KSNBIF
3$16,589$1,497.73$12,538$822.59+$4.1KSNBIF
4$19,396$1,646.38$13,645$956.06+$5.8KSNBIF
5$22,553$1,799.08$14,925$1,116.51+$7.6KSNBIF
6$26,087$1,955.04$16,415$1,310.57+$9.7KSNBIF
7$30,027$2,113.43$18,158$1,546.77+$11.9KSNBIF
8$34,402$2,273.44$20,213$1,836.20+$14.2KSNBIF
9$39,244$2,434.31$22,649$2,193.37+$16.6KSNBIF
10$44,587$2,595.30$25,558$2,637.42+$19.0KSNBIF

SNBIF vs NNN: Complete Analysis 2026

SNBIFStock

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.

Full SNBIF Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this SNBIF vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNBIF vs SCHDSNBIF vs JEPISNBIF vs OSNBIF vs KOSNBIF vs MAINSNBIF vs ADCSNBIF vs EPRTSNBIF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.